Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Buys Ebewe’s Injectable Cancer Drug Business

This article was originally published in The Pink Sheet Daily

Executive Summary

The €925 million deal provides Novartis’ Sandoz division with a fast-growing generic oncology business and expanded development portfolio.

You may also be interested in...



Is Teva Among Finalists In Bidding For Germany's Ratiopharm? (Part 2 of 2)

Ratiopharm would bring market share, geographic diversification, and an attractive OTC business - if the price is right.

Is Teva Among Finalists In Bidding For Germany's Ratiopharm? (Part 2 of 2)

Ratiopharm would bring market share, geographic diversification, and an attractive OTC business - if the price is right.

Generic Injectables: Pharma Takes A Shot At A Growing Market

When it comes to drugs driving generic growth, usually blockbusters such as Lipitor and Plavix come to mind. But there is another area of the generic market that offers plenty of dynamic potential - sterile drugs administered by injection or infusion

Related Content

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel